New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4487-4497

  Gordeev, Mikhail F ^a   Yuan, Zhengyu Y ^a  

^a MicuRx Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(ISOXAZOL 3 YLAMINO)METHYL] 3 [2,3,5 TRIFLUORO 4 [4 OXO 3,4 DIHYDROPYRIDIN 1(2H) YL]PHEYL]OXAZOLIDIN 2 ONE; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; GRAM POSITIVE BACTERIUM; HUMAN; MEDICINAL CHEMISTRY; NONHUMAN;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BONE MARROW CELLS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; OXAZOLIDINONES; PYRIDONES; SEPSIS;

EID: 84902477549     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401931e     Document Type: Article

References (53)

1. Rich, M. L.; Ritterhoff, R. J.; Hoffmann, R.J. M.D. A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy Ann. Int. Med. 1950, 33, 1459-1467
2. Kux, L. Determination that chloromycetin (chloramphenicol) capsules, 250 mg, were withdrawn from sale for reasons of safety or effectiveness. Fed. Regist. Not. 2012, 77, Friday, July 13.
3. Ross, D. B. The FDA and the case of Ketek N. Engl. J. Med. 2007, 356, 1601-1604 (Pubitemid 46631668)
4. Paul A Dieppe, P. A.; Ebrahim, S.; Jüni, P. Lessons from the withdrawal of rofecoxib Br. Med. J. 2004, 329, 867-868 (Pubitemid 39422926)
5. FDA's Sentinel Initiative; U.S. Food and Drug Administration: Silver Spring, MD; http://www.fda.gov/Safety/FDAsSentinelinitiative/ucm2007250.htm.
6. Ford, C. W.; Zurenko, G. E.; Barbachyn, M. R. The discovery of linezolid, the first oxazolidinone antibacterial agent Curr. Drug Targets Infect. Dis. 2001, 181-199
7. Brickner, S. J.; Barbachyn, M. R.; Hutchinson, D. K.; Manninen, P. R. Linezolid (Zyvox), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections J. Med. Chem. 2008, 51, 1981-1990 (Pubitemid 351503251)
8. Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents Expert Opin. Invest. Drugs 1999, 8, 1195-1202 (Pubitemid 29410576)
9. Jones, R. N.; Ross, J. E.; Bell, J. M.; Utsuki, U.; Fumiaki, I.; Kobayashi, I.; Turnidge, J. D. Zyvox annual appraisal of potency and spectrum program: linezolid surveillance program results for 2008 Diagn. Microb. Infect. Dis. 2009, 65, 404-413
10. Ross, J. E.; Flamm, R. K.; Sader, H. S.; Hogan, P. A.; Jones, R. N. Report of linezolid activity from the Zyvox annual appraisal of potency and spectrum (ZAAPS) program 2012 (Europe, Latin America, Asia Pacific, Canada). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013, Poster C2-088.
11. Pucci, M. J.; Bush, K. Investigational antimicrobial agents of 2013 Clin. Microb. Rev. 2013, 26, 792-821
12. Vinh, D. C.; Rubinstein, E. Linezolid: a review of safety and tolerability J. Infect. 2009, 59, S59-S74
13. Nagiec, E. E.; Wu, L.; Chosay, J. G.; Ross, D. E.; Brieland, J. K.; Leach, K. L. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis Antimicrob. Agents Chemother. 2005, 3896-3902 (Pubitemid 41233047)
14. Attassi, K.; Hershberger, E.; Alam, R.; Zervos, M. J. Thrombocytopenia associated with linezolid therapy Clin. Infect. Dis. 2002, 34, 695-698 (Pubitemid 34165334)
15. Li, J.; Tripathi, R. C.; Tripathi, B. J. Drug-induced ocular disorders Drug Saf. 2008, 31, 127-141 (Pubitemid 351158524)
16. Kulkarni, K.; Del Priore, L. V.; Kulkarni, K. Linezolid induced toxic optic neuropathy Br. J. Opthalmol. 2005, 89, 1664-1665 (Pubitemid 41729921)
17. Rucker, J. C.; Hamilton, S. R.; Bardenstein, D.; Isada, C. M.; Lee, M. S. Linezolid-associated toxic optic neuropathy Neurology 2006, 66, 595-598 (Pubitemid 43739898)
18. Azamfirei, L.; Copotoiu, S.-M.; Branzanuic, K.; Szederjesi, J.; Copotoiu, R.; Berteanu, C. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy Pharmacoepidemiol. Drug Saf. 2007, 16, 402-404 (Pubitemid 46656861)
19. Prescribing Information for Zyvox, LAB-0139-20.0, revised June 2010; Pfizer: New York, 2010.
20. Gordeev, M. F.; Prasad, J. V. N.; Luehr, G. W. 7-Fluoro-1,3-Dihydroindol- 2-one oxazolidinones as antibacterial agents. PCT WO 2006/106427, Oct 12, 2006.
21. Choy, A.; Colbry, N.; Pamment, M.; Van Duine, J. Development of a synthesis for a long-term oxazolidinone antibacterial Org. Process Res. Dev. 2008, 12, 884-887
22. Huband, M. D.; Mullins, L. M.; Pagano, P. J.; Penzie, J. B.; McCurdy, S. P.; Lemmon, M. M.; Gibson, G. W; Leach, K.; Qiu, L.; Vara Prasad, J. V. N.; Renslo, A.; Luehr, G. W.; Jain, R.; Gordeev, M. F. In vitro and in vivo activity of PF-03315011: a new oxazolidinone antibacterial versus recent bacterial clinical isolates. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, April 10-13, 2010.
23. Dryden, M. S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J. Antimicrob. Chemother. 2011, 66 (Suppl 4) iv7-iv17
24. Huang, V.; Gortney, J. S. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists Pharmacotherapy 2006, 26, 1784-1793 (Pubitemid 44885332)
25. Im, W. B.; Choi, S. H.; Park, J.-Y.; Choi, S. H.; Finn, J.; Yoon, S.-H. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent Eur. J. Med. Chem. 2011, 46, 1027-1039
26. Kanafani, Z. A.; Corey, G. R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency Expert Opin. Invest. Drugs. 2012, 21, 515-522
27. Fang, E.; De Anda, C.; Das, A.; Prokocimer, P. Safety profile of tedizolid phosphate compared to linezolid in a Phase 3 ABSSSI study. 52nd Intersci. Conf. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster L1-1664.
28. Das, D.; Lambert, A.; Tulkens, P. M.; Muccioli, G. G.; Van Bembeke, F. Study of the cellular uptake and subcellular distribution of the oxazolidinone tedizolid (TZD) in murine J774 macrophages: lack of association with mitochondria. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster A-1291.
29. Zhu, D. M.; Wang, W.; Huang, Y. Q.; Zhang, Y. Y. Antibacterial spectrum of oxazolidinone MRX-I: potent activity against multidrug-resistant Gram-positive pathogens. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1497.
30. Huang, Y. Q.; Wang, W.; Li, Y.; Wang, H. L.; Xu, Y. H.; Liu, C.; Zhou, F.; Wang, C. Q.; Liu, J.; Wang, Q. Antimicrobial profile of MRX-I: resistance and drug combination studies. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1498.
31. Li, C. R.; Li, G. Q.; Hu, X. X.; Zhang, W. X.; Wang, X. K.; Pang, J.; Lu, X.; Zhai, Q. Q.; Yuan, H.; Gordeev, M. F.; Yang, X. Y.; You, X. F. Novel oxazolidinone MRX-I is efficacious in mouse models of Gram-positive bacterial infections. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1499.
32. Chen, X. Y.; Gao, Z. W.; Yuan, H.; Yuan, Z. Y.; Zhong, D. F. Pre-clinical pharmacokinetics of MRX-I in rodents and dogs. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1500.
33. Wang, W.; Wang, Z.; Chang, Y.; Yuan, H.; Yuan, Z. Y.; Zhou, J. L.; Zhong, D. F. In vitro safety study of MRX-I, a safer oxazolidinone antibacterial agent. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1501.
34. Qiu, Y. L.; Jiang, J. Q.; Huang, H. X.; Hsu, C. H.; Ma, J.; Yuan, H.; Gordeev, M. F. Acute and repeat dose toxicity of MRX-I in rat. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1502.
35. Zhang, J.; Wu, X. J.; Huang, J.; Yu, J. C.; Guo, B. N.; Cao, G. Y.; Wu, J. F.; Zhang, K. J.; Yuan, H.; Yuan, Z. Y.; Shi, Y. G.; Zhang, Y. Y. Single oral dose pharmacokinetics of MRX-I in healthy subjects. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1503.
36. Zhang, J.; Wu, X. J.; Huang, J.; Yu, J. C.; Guo, B. N.; Cao, G. Y.; Wu, J. F.; Yuan, H.; Yuan, Z. Y.; Shi, Y. G.; Zhang, Y. Y. Hematological effect and pharmacokinetics of multiple oral dose MRX-I in healthy subjects. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster F-1504.
37. Brickner, S. J. Oxazolidinone antibacterial agents Curr. Pharm. Des. 1996, 2, 175-194 (Pubitemid 126474511)
38. Park, C.-H.; Britelli, D. R.; Wang, C. L.-J.; Marsh, F. D.; Gregory, W. A.; Wuonola, M. A.; McRipley, R. J.; Eberly, V. S.; Slee, A. M.; Forbes, M. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2- oxooxazolidines. 4. Multiply-substituted aryl derivatives J. Med. Chem. 1992, 35, 1156-1165
39. Hutchinson, D. K. Oxazolidinone antibacterial agents: a critical review Curr. Top. Med. Chem. 2003, 3, 1021-1042
40. Renslo, A. R. Antibacterial oxazolidinones: emerging structure-toxicity relationships Expert. Rev. Anti-infect. Ther. 2010, 8, 565-574
41. Gordeev, M. F.; Upinder, S.; Patel, D. V.; May, P. D. Antimicrobial 1-aryl dihydropyridone compounds. PCT WO 2004/033449, Apr 22, 2004.
42. Rhee, J. K.; Im, W. B.; Cho, C. H.; Choi, S. H.; Lee, T. H. Novel oxazolidinone derivatives. PCT WO 2005/058886, Jun 30, 2005.
43. Renslo, A. R.; Luehr, G. W.; Gordeev, M. F. Recent developments in the identification of novel oxazolidinone antibacterial agents Bioorg. Med. Chem. 2006, 4227-4240
44. Barbachyn, M. R.; Harris, C. R.; Vara Prasad, J. V. N. Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents. PCT WO 2005/113520, Dec 1, 2005.
45. Harris, C. R.; Barbachyn, M. R.; Vara Prasad, J. V. N.; Angell, P.; Fusen Han; Sulavik, M. C.; Gibson, G. W.; Gage, G. W.; Lockard, M.; Ford, C. W.; Hamel, J. C.; Stapert, M. D.; Huband, M. D.; Pagano, P. J.; Zurenko, G. E.; Schaadt, R. D.; Yagi, B. H.; Ogden, A. G.; Lepsy, C. S.; Ashton, B.; Hollembaek, J. M.; Brodfuehrer, J. I.; Adams, W. J.; Martin, Jr., J. P.; Blackburn, A. C.; Spence, J. Identification of a new trifluorophenyl oxazolidinone, PF-00987296. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 27-30, 2006, Poster F1-0971.
46. Parchment, R. E.; Gordon, M.; Grieshaber, C. K.; Sessa, C.; Volpe, D.; Ghielmini, M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests Ann. Oncol. 1998, 9, 357-364 (Pubitemid 28273026)
47. Gordeev, M. F. Antimicrobial ortho -fluorophenyl oxazolidinones for treatment of bacterial infections. PCT WO 2009/020616, Feb 12, 2009.
48. Technical Bulletin "MAO-Glo Assay"; Promega Co.: Madison, WI.
49. Leach, K. L. Assay for myelosuppression. PCT WO 2006/097828, Sept 21, 2006.
50. Huang, Y.-Q.; Xu, Y.-H.; Liu, S.-C.; Wang, H.-L.; Xu, X.-G.; Guo, Q.-L.; Wu, B.-X.; Gordeev, M. F.; Wang, W.; Yuan, Z. Y.; Wang, M.-G. Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I. Int. J. Antimicrob. Agents, 2014, DOI: 10.1016/j.ijantimicag.2014.02.008.
51. Slatter, J. G.; L. A. Adams, L. A.; Bush, E. C.; Chiba, K.; Daley-Yates, P. T.; Feenstra, K. L.; Koike, S.; Ozawa, N.; Peng, G. W.; Sams, J. P.; Schuette, M. R.; Yamazaki, S. Xenobiotica 2002, 32, 907-924
52. Technical Bulletin "Fluoro-MAOTM Assay"; Peninsula Laboratories, Inc. (USA): San Carlos, CA.
53. Fang, E.; De Anda, C.; Prokocimer, P. Safety profile of tedizolid phosphate compared to linezolid in a phase 3 ABSSSI study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 9-12, 2012, Poster L1-1664.